title: Cutaneous involvement in multiple myeloma and bortezomib.
authors.forename: A
authors.initials: A
authors.lastname: Siniscalchi
authors.forename: S
authors.initials: S
authors.lastname: Fratoni
authors.forename: G
authors.initials: G
authors.lastname: Santeusanio
authors.forename: G
authors.initials: G
authors.lastname: Del Poeta
authors.forename: P
authors.initials: P
authors.lastname: de Fabritiis
authors.forename: T
authors.initials: T
authors.lastname: Caravita
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009194:Myeloma Proteins / Q000032:analysis; D010292:Paresthesia / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D010950:Plasma Cells / Q000187:drug effects* / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D012074:Remission Induction; D012867:Skin / Q000473:pathology*; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects; D014985:Xerophthalmia / Q000139:chemically induced
chemical_list: D001897:Boronic Acids; D007070:Immunoglobulin A; D009194:Myeloma Proteins; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D008558:Melphalan; D011241:Prednisone